Inpharma 1627 - 1 Mar 2008

FDA grants accelerated approvalfor bevacizumab

The FDA has granted Genentech accelerated approvalfor bevacizumab [Avastin] in combination withpaclitaxel as first-line therapy in patients with advancedHER2-negative breast cancer.

A full review of the phase III AVADO and RIBBON-1trial data by the FDA will be required for the acceleratedapproval to be renewed to a full approval. Roche is thelicensee for this product.Roche. FDA grants accelerated approval of Avastin in combination with paclitaxelchemotherapy for first-line treatment of patients with advanced HER2-negativebreast cancer. Media Release : 23 Feb 2008. Available from: URL: http://www.roche.com 809085600

1

Inpharma 1 Mar 2008 No. 16271173-8324/10/1627-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved